Medtronic Surpasses Earnings Expectations, Stock Rises 5.3%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: Fool
- Strong Earnings Report: Medtronic reported Q4 fiscal 2026 earnings of $1.55 per share, exceeding analyst expectations of $1.54, with sales reaching $9.8 billion, reflecting a robust performance in the medical device sector.
- Robust Organic Growth: Of the sales increase, 6.6% came from organic growth, while acquisitions contributed to the company's highest annual revenue growth in a decade, indicating sustained competitiveness in the market.
- Annual Performance Review: Although total sales growth for fiscal 2026 was 8.4%, the acceleration in growth during Q4 suggests a recovery in market demand, with the final quarter outperforming the annual average.
- Future Outlook: Medtronic forecasts about 7% organic sales growth for fiscal 2027, slightly lower than previous periods, but with non-GAAP profit expectations ranging from $5.90 to $6.00, indicating stable earnings growth potential, and a 3.8% dividend yield suggests the stock is reasonably valued.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDT
Wall Street analysts forecast MDT stock price to rise
20 Analyst Rating
11 Buy
9 Hold
0 Sell
Moderate Buy
Current: 81.930
Low
102.00
Averages
111.76
High
120.00
Current: 81.930
Low
102.00
Averages
111.76
High
120.00
About MDT
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medtronic Announces Key Milestones for Hugo™ RAS System Expansion
- 510(k) Filing Progress: Medtronic has submitted 510(k) filings for the Hugo™ RAS system's use in general and gynecological surgeries, which is expected to significantly broaden the platform's clinical applicability in the U.S. to meet the growing demand for robotic-assisted minimally invasive options.
- LigaSure™ RAS Instrument Approval: The company announced the submission of the 510(k) application for the LigaSure™ RAS Maryland instrument, which has been utilized in over 35 million procedures globally, enhancing surgeons' confidence and control during complex surgeries.
- ProGrip™ Advanced Mesh Approval: Medtronic received 510(k) clearance for the ProGrip™ Advanced self-gripping polypropylene mesh, which has been used in more than 6 million procedures, aimed at improving efficiency and safety in robotic-assisted ventral hernia repair surgeries.
- Embrace Gynecology Study Enrollment Complete: Medtronic announced the completion of enrollment in the Embrace Gynecology IDE clinical study, involving 70 patients, aimed at evaluating the safety and effectiveness of the Hugo™ RAS system in robotic-assisted gynecological procedures.
See More
Lowe's, Medtronic, and UnitedHealth Raise Dividends
- Lowe's Dividend Increase: Lowe's announced a 4% increase in its quarterly dividend to $1.25 per share, and despite a 14% decline in stock price this year, its 2.4% yield remains significantly above the S&P 500's 1% average.
- Medtronic's Revenue Growth: Medtronic reported an 8.4% annual revenue growth for fiscal 2026, reaching $36.4 billion, and raised its dividend to $0.72, marking the 49th consecutive year of increases, underscoring its appeal as a quality dividend stock.
- UnitedHealth's Dividend Boost: UnitedHealth increased its quarterly dividend by 5% to $2.32 per share, with a 60% rise over the past five years, averaging a compounded annual growth rate of about 10%, providing investors with a hedge against inflation.
- Healthcare Sector Outlook: While Medtronic and UnitedHealth's stock prices have fallen by 15% and risen by 20% respectively this year, their forward P/E ratios of 12 and 21 indicate strong appeal for dividend investors, particularly in the medical devices and health insurance sectors.
See More
Three High-Yield Stocks Increase Dividends
- Lowe's Dividend Increase: Lowe's announced a 4% increase in its quarterly dividend to $1.25 per share, yielding 2.4%, which is significantly higher than the S&P 500's 1%, despite a 14% drop in stock price this year; this move underscores the company's long-standing commitment to dividend payments, as home repairs remain essential for homeowners in the long run.
- Medtronic Annual Performance: Medtronic reported a record revenue of $36.4 billion for fiscal 2026, an 8.4% increase year-over-year, and raised its dividend to $0.72 per share, marking the 49th consecutive year of increases; while the increment is modest, its 3.5% yield continues to attract investors, reflecting its solid position in the medical device sector.
- UnitedHealth Dividend Boost: UnitedHealth increased its quarterly dividend by 5% to $2.32 per share, with a remarkable 60% rise over the past five years, averaging a 10% compound annual growth rate, which not only offsets inflation but also boosts investor confidence in its future performance, as the stock has risen 20% this year while remaining reasonably priced.
- Market Outlook Analysis: All three companies demonstrate strong performance in their respective sectors, and despite market fluctuations, Lowe's and Medtronic's low P/E ratios of 16 and 12 make them attractive options for investors, while UnitedHealth's improved control over medical expenses provides confidence for future growth.
See More
US Stocks Close Mixed: Dow Hits All-Time High
- Dow Hits Record High: The Dow Jones Industrial Average rose 1.73% to reach an all-time high, reflecting strong rebounds in bank and managed healthcare stocks, despite a 0.53% decline in the Nasdaq 100 due to weakness in technology stocks.
- Crude Oil Prices Decline: WTI crude oil prices fell over 3%, lowering inflation expectations and pushing the 10-year T-note yield down 2 basis points to 4.47%, providing support for both stock and bond markets, indicating a complex market reaction to economic outlooks.
- Jobless Claims Rise: Initial jobless claims in the US increased by 13,000 to 225,000, marking a 3.75-month high, suggesting a weaker labor market, although unit labor costs were unexpectedly revised down to 1.8%, easing concerns over wage pressures.
- Earnings Season Summary: As of Thursday, 83% of the 494 S&P 500 companies reported earnings that beat estimates, with Q1 earnings projected to rise 12% year-over-year, but excluding the tech sector, growth is only about 3%, the lowest in two years, reflecting divergence across industries.
See More
Dow Jones Hits All-Time High Amid Mixed Market Performance
- Dow Jones High: The Dow Jones Industrial Average surged 1.49% to reach a new all-time high, demonstrating market resilience driven by strong performance in managed healthcare stocks, despite overall market pressures.
- Tech Sector Decline: Broadcom's stock plummeted over 14% due to disappointing AI revenue forecasts, leading to a broader decline in chipmakers, while CrowdStrike fell more than 8% despite beating Q1 earnings expectations, reflecting market caution towards tech stocks.
- Mixed Economic Data: Initial jobless claims rose to 225,000, a 3.75-month high, indicating a weaker labor market, while Q1 nonfarm productivity was revised down to 0.3%, below expectations, potentially impacting future economic growth outlooks.
- Oil Price Impact: WTI crude oil prices fell over 3% amid a ceasefire agreement between Israel and Lebanon, which lowered inflation expectations and provided support for both stock and bond markets, improving investor sentiment.
See More
Alnylam Partners with Inceptive in AI Collaboration
- Strategic Collaboration: Alnylam Pharmaceuticals has entered into a strategic AI partnership with Inceptive Nucleics valued at up to $2 billion, aiming to leverage Inceptive's generative AI models to accelerate the discovery of RNA interference therapeutics, thereby enhancing its competitive edge in the biopharmaceutical sector.
- Market Rebound: Blackstone's shares rose 8% despite the firm limiting withdrawals from its Private Credit fund, indicating investor confidence as the stock is poised to end a three-day losing streak, reflecting a positive sentiment towards asset management firms.
- Stock Volatility: Broadcom's shares tumbled nearly 15% after reporting second-quarter revenue of $22.19 billion, falling short of the $22.27 billion expected by analysts, although CEO Hock Tan reiterated the company's fiscal year 2027 revenue guidance for AI chips to exceed $100 billion, raising concerns about future growth prospects.
- Healthcare Outlook: UnitedHealth's stock climbed 5% following an upgrade from Bank of America from neutral to buy, citing improving medical cost trends and supportive near-term data points that are expected to favorably impact second-quarter earnings, reflecting optimism in the health insurance sector.
See More
Medtronic Announces Key Milestones for Hugo™ RAS System Expansion
- 510(k) Filing Progress: Medtronic has submitted 510(k) filings for the Hugo™ RAS system's use in general and gynecological surgeries, which is expected to significantly broaden the platform's clinical applicability in the U.S. to meet the growing demand for robotic-assisted minimally invasive options.
- LigaSure™ RAS Instrument Approval: The company announced the submission of the 510(k) application for the LigaSure™ RAS Maryland instrument, which has been utilized in over 35 million procedures globally, enhancing surgeons' confidence and control during complex surgeries.
- ProGrip™ Advanced Mesh Approval: Medtronic received 510(k) clearance for the ProGrip™ Advanced self-gripping polypropylene mesh, which has been used in more than 6 million procedures, aimed at improving efficiency and safety in robotic-assisted ventral hernia repair surgeries.
- Embrace Gynecology Study Enrollment Complete: Medtronic announced the completion of enrollment in the Embrace Gynecology IDE clinical study, involving 70 patients, aimed at evaluating the safety and effectiveness of the Hugo™ RAS system in robotic-assisted gynecological procedures.
See More
Lowe's, Medtronic, and UnitedHealth Raise Dividends
- Lowe's Dividend Increase: Lowe's announced a 4% increase in its quarterly dividend to $1.25 per share, and despite a 14% decline in stock price this year, its 2.4% yield remains significantly above the S&P 500's 1% average.
- Medtronic's Revenue Growth: Medtronic reported an 8.4% annual revenue growth for fiscal 2026, reaching $36.4 billion, and raised its dividend to $0.72, marking the 49th consecutive year of increases, underscoring its appeal as a quality dividend stock.
- UnitedHealth's Dividend Boost: UnitedHealth increased its quarterly dividend by 5% to $2.32 per share, with a 60% rise over the past five years, averaging a compounded annual growth rate of about 10%, providing investors with a hedge against inflation.
- Healthcare Sector Outlook: While Medtronic and UnitedHealth's stock prices have fallen by 15% and risen by 20% respectively this year, their forward P/E ratios of 12 and 21 indicate strong appeal for dividend investors, particularly in the medical devices and health insurance sectors.
See More
Three High-Yield Stocks Increase Dividends
- Lowe's Dividend Increase: Lowe's announced a 4% increase in its quarterly dividend to $1.25 per share, yielding 2.4%, which is significantly higher than the S&P 500's 1%, despite a 14% drop in stock price this year; this move underscores the company's long-standing commitment to dividend payments, as home repairs remain essential for homeowners in the long run.
- Medtronic Annual Performance: Medtronic reported a record revenue of $36.4 billion for fiscal 2026, an 8.4% increase year-over-year, and raised its dividend to $0.72 per share, marking the 49th consecutive year of increases; while the increment is modest, its 3.5% yield continues to attract investors, reflecting its solid position in the medical device sector.
- UnitedHealth Dividend Boost: UnitedHealth increased its quarterly dividend by 5% to $2.32 per share, with a remarkable 60% rise over the past five years, averaging a 10% compound annual growth rate, which not only offsets inflation but also boosts investor confidence in its future performance, as the stock has risen 20% this year while remaining reasonably priced.
- Market Outlook Analysis: All three companies demonstrate strong performance in their respective sectors, and despite market fluctuations, Lowe's and Medtronic's low P/E ratios of 16 and 12 make them attractive options for investors, while UnitedHealth's improved control over medical expenses provides confidence for future growth.
See More
US Stocks Close Mixed: Dow Hits All-Time High
- Dow Hits Record High: The Dow Jones Industrial Average rose 1.73% to reach an all-time high, reflecting strong rebounds in bank and managed healthcare stocks, despite a 0.53% decline in the Nasdaq 100 due to weakness in technology stocks.
- Crude Oil Prices Decline: WTI crude oil prices fell over 3%, lowering inflation expectations and pushing the 10-year T-note yield down 2 basis points to 4.47%, providing support for both stock and bond markets, indicating a complex market reaction to economic outlooks.
- Jobless Claims Rise: Initial jobless claims in the US increased by 13,000 to 225,000, marking a 3.75-month high, suggesting a weaker labor market, although unit labor costs were unexpectedly revised down to 1.8%, easing concerns over wage pressures.
- Earnings Season Summary: As of Thursday, 83% of the 494 S&P 500 companies reported earnings that beat estimates, with Q1 earnings projected to rise 12% year-over-year, but excluding the tech sector, growth is only about 3%, the lowest in two years, reflecting divergence across industries.
See More
Dow Jones Hits All-Time High Amid Mixed Market Performance
- Dow Jones High: The Dow Jones Industrial Average surged 1.49% to reach a new all-time high, demonstrating market resilience driven by strong performance in managed healthcare stocks, despite overall market pressures.
- Tech Sector Decline: Broadcom's stock plummeted over 14% due to disappointing AI revenue forecasts, leading to a broader decline in chipmakers, while CrowdStrike fell more than 8% despite beating Q1 earnings expectations, reflecting market caution towards tech stocks.
- Mixed Economic Data: Initial jobless claims rose to 225,000, a 3.75-month high, indicating a weaker labor market, while Q1 nonfarm productivity was revised down to 0.3%, below expectations, potentially impacting future economic growth outlooks.
- Oil Price Impact: WTI crude oil prices fell over 3% amid a ceasefire agreement between Israel and Lebanon, which lowered inflation expectations and provided support for both stock and bond markets, improving investor sentiment.
See More
Alnylam Partners with Inceptive in AI Collaboration
- Strategic Collaboration: Alnylam Pharmaceuticals has entered into a strategic AI partnership with Inceptive Nucleics valued at up to $2 billion, aiming to leverage Inceptive's generative AI models to accelerate the discovery of RNA interference therapeutics, thereby enhancing its competitive edge in the biopharmaceutical sector.
- Market Rebound: Blackstone's shares rose 8% despite the firm limiting withdrawals from its Private Credit fund, indicating investor confidence as the stock is poised to end a three-day losing streak, reflecting a positive sentiment towards asset management firms.
- Stock Volatility: Broadcom's shares tumbled nearly 15% after reporting second-quarter revenue of $22.19 billion, falling short of the $22.27 billion expected by analysts, although CEO Hock Tan reiterated the company's fiscal year 2027 revenue guidance for AI chips to exceed $100 billion, raising concerns about future growth prospects.
- Healthcare Outlook: UnitedHealth's stock climbed 5% following an upgrade from Bank of America from neutral to buy, citing improving medical cost trends and supportive near-term data points that are expected to favorably impact second-quarter earnings, reflecting optimism in the health insurance sector.
See More
